Conditions: Solid Tumors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 17
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate the safety and tolerability of LY2603618 in combination with the standard dose of gemcitabine up to the global recommended dose of LY2603618 in Japanese participants with solid advanced or metastatic tumors.

Detailed description:

Arms:
arm 1: Gemcitabine 1000 milligrams per meter squared (mg/m\^2) administered intravenously on days 1, 8 and 15 of at least one 28-day cycle. 170 or 230 mg LY2603618 administered intravenously on days 2, 9 and 16 of at least one 28-day cycle.

Participants experiencing benefit may continue on the combination therapy until discontinuation criteria are met.

Interventions: intervention 1: LY2603618 intervention 2: Gemcitabine
Intervention descriptions: intervention 1: Administered intravenously intervention 2: Administered intravenously

Protocol document: